Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [11] Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11
    Parker, Gregory S.
    Toth, Julia I.
    Fish, Sarah
    Blanco, Gabrielle
    Kampert, Taylor
    Li, Xiaoming
    Yang, Linette
    Stumpf, Craig R.
    Steadman, Kenneth
    Jamborcic, Aleksandar
    Chien, Stephen
    Daniele, Elizabeth
    Dearie, Alejandro
    Leriche, Geoffray
    Bailey, Simon
    Thompson, Peggy A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1446 - 1458
  • [12] Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis
    He, Zhangxu
    Jiao, Haomiao
    An, Qi
    Zhang, Xin
    Zengyangzong, Dan
    Xu, Jiale
    Liu, Hongmin
    Ma, Liying
    Zhao, Wen
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (01) : 291 - 307
  • [13] Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4
    Yokoyama, Takeshi
    Matsumoto, Kazunori
    Ostermann, Andreas
    Schrader, Tobias E.
    Nabeshima, Yuko
    Mizuguchi, Mineyuki
    FEBS JOURNAL, 2019, 286 (09) : 1656 - 1667
  • [14] Discovery, optimization and biological evaluation of chromone derivatives as novel BRD4 inhibitors
    Jia, Zhao-Tong
    Li, You
    Shi, Wei
    Qian, Jian-Qiang
    Xu, Ya-Yu
    Fan, Hai-Ran
    Hu, Xiao-Long
    Wang, Hao
    MEDICINAL CHEMISTRY RESEARCH, 2025, 34 (03) : 720 - 744
  • [15] Structural variation of protein-ligand complexes of the first bromodomain of BRD4
    Guest, Ellen E.
    Pickett, Stephen D.
    Hirst, Jonathan D.
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2021, 19 (25) : 5632 - 5641
  • [16] Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
    Li, Junhua
    Hu, Qingqing
    Zhu, Run
    Dong, Ruibo
    Shen, Hui
    Hu, Jiankang
    Zhang, Cheng
    Zhang, Xiaohan
    Xu, Tingting
    Xiang, Qiuping
    Zhang, Yan
    Lin, Bin
    Zhao, Linxiang
    Wu, Xishan
    Xu, Yong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (23) : 21577 - 21616
  • [17] Discovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy
    Huang, Zifeng
    Chu, Tong
    Ma, Aijun
    Lin, Wanjun
    Gao, Yan
    Zhang, Na
    Shi, Meina
    Zhang, Xuening
    Yang, Yanchao
    Ma, Wenzhe
    BIOCHEMICAL PHARMACOLOGY, 2025, 235
  • [18] Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity
    Chen, Shuxia
    Yang, Jichen
    Wang, Xiangyu
    Liu, Xiaochun
    Li, Xiuxue
    Ye, Yansheng
    Wang, Pingyuan
    Liu, Zhiqing
    Wang, Chang-Yun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 284
  • [19] Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays
    Sun, Zhongya
    Zhang, Hao
    Chen, Zhifeng
    Xie, Yiqian
    Jiang, Hao
    Chen, Limin
    Ding, Hong
    Zhang, Yuanyuan
    Jiang, Hualiang
    Zheng, Mingyue
    Luo, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (09) : 2003 - 2009
  • [20] Discovery of dual CDK4/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo
    Zhang, Yonglei
    Luo, Zhongwen
    Jiang, Yuhan
    Zheng, Long
    Ma, Liangliang
    Zheng, Yiwei
    Zou, Meiting
    Kong, Lingyi
    Wang, Xiaobing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 290